GlassScriptPhysician profile
Craig A Clark
NPI 1164529186
$31,435.51
in general payments reported to CMS, 2019-2025
27 companies · $693 in 2025
The $693 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,328 · 2020: $131 · 2021: $22K · 2022: $877 · 2023: $1,117 · 2024: $882 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21,900.77 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $6,623.16 | 2019-2025 | Trintellix |
| Abbvie INC. | $446.93 | 2021-2025 | Vraylar |
| Corium, LLC | $358.18 | 2022-2025 | Azstarys |
| Tris Pharma INC | $324.81 | 2019-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $267.37 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $213.34 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $183.43 | 2019-2024 | Spravato |
| Alkermes, INC. | $167.85 | 2022-2023 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $145.54 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $121.58 | 2024-2025 | Fanapt, Hetlioz |
| Adlon Therapeutics L.P. | $101.79 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $71.31 | 2021-2022 | |
| Lundbeck LLC | $66.89 | 2019-2024 | Rexulti |
| Brainsway USA INC | $66.32 | 2021-2025 | Brainsway Deep Tms System, Deep Tms System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $63.72 | 2024 | Xelstrym, Secuado |
| Allergan, INC. | $59.29 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.50 | 2025 | Caplyta |
| Tempus Ai, INC | $42.35 | 2024 | |
| Vertical Pharmaceuticals, LLC | $37.80 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.67 | 2022 | |
| Neuronetics, INC. | $20.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.40 | 2021 | |
| Neos Therapeutics, LP | $17.05 | 2019 | |
| Avion Pharmaceuticals | $16.73 | 2023 | Methylphenidate Hydrochloride |
| Alfasigma USA, INC. | $13.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.